Autoimmune Disease Diagnosis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Consumables & Assay Kits, Instruments), By Test Type (Routine Laboratory Tests, Inflammatory Markers, Autoantibodies & Immunologic Test, Other Tests), By Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Thyroiditis, Scleroderma, Other Diseases), By End-user Industry (Clinical Laboratories, Hospitals, Other End Users) and Region Forecast 2019-2030

Autoimmune Disease Diagnosis Market size was valued at US$ 4,376.3 million in 2023 and is poised to grow at a significant CAGR of 6.5% from 2024-2030. An autoimmune disease develops when autoimmune cells in the body fail to distinguish between self and non-self-cells, resulting in an immunogenic reaction against the body's own cells. Several scientific and technical advances have resulted in accurate and rapid diagnosis tools for autoimmune diseases. MiRNAs have critical roles in numerous biological processes that regulate innate and adaptive immune cell development, maturation, and activation in adaptive immune systems. The consumables & assay kits segment is anticipated to grow at a significant CAGR over the forecast years owing to increased extensive usage of ATP assays kits in research institutes to measure cell viability and improve drug discovery due to a surge in chronic diseases that requires tumor testing and cell proliferation (in cancer).

Moreover, repeated purchase of consumables by pharmaceutical and biotechnology companies anticipated the segment growth. In addition, Market players focus on launching a new product, collaborating, and acquisitions. For instance, In June 2022, Thermo Scientific launched new EliA RNA Pol III and EliA Rib-P blood tests for the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematous.The rising prevalence of the chronic disease is a key factor surge the autoimmune disease diagnosis market revenue in the future. Moreover, rise in funding from public and private organizations for the development of advanced tests and favorable reimbursement policies are a few factors driving the industry's growth over the forecasting period.  

Key Developments

• In 2019, PerkinElmer, Inc. received approval from the US FDA EUROIMMUN Anti-Tissue Transglutaminase ELISA to help clinicians confirm or exclude a celiac disease diagnosis.
• In 2019, Exagen Inc. (US) extended its agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management.